Skip to main content
Frank Jacono, MD, Pulmonology, Cleveland, OH

FrankJJaconoMD

Pulmonology Cleveland, OH

Critical Care Medicine, Pleural Disease

Associate Professor, Medicine, Case Western Reserve University School of Medicine

Dr. Jacono is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Jacono's full profile

Already have an account?

  • Office

    11100 Euclid Ave
    Cleveland, OH 44106
    Phone+1 216-844-8500
    Fax+1 216-421-3217

Education & Training

  • Case Western Reserve University/University Hospitals Cleveland Medical Center
    Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2001 - 2004
  • Case Western Reserve University/University Hospitals Cleveland Medical Center
    Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1998 - 2001
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 1998

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2004 - 2026
  • American Board of Internal Medicine Critical Care Medicine
  • American Board of Internal Medicine Pulmonary Disease

Publications & Presentations

PubMed

Press Mentions

  • Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS
    Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDSMay 5th, 2020
  • Athersys and University Hospitals Cleveland Medical Center Announce Activation of the First Clinical Site for the MACOVIA Study, a Pivotal Phase 2/3 Study Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS
    Athersys and University Hospitals Cleveland Medical Center Announce Activation of the First Clinical Site for the MACOVIA Study, a Pivotal Phase 2/3 Study Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDSMay 1st, 2020
  • UH Cleveland Medical Center Will Be the First Clinical Site for a New Athersys Inc. Trial
    UH Cleveland Medical Center Will Be the First Clinical Site for a New Athersys Inc. TrialMay 1st, 2020
  • Join now to see all